XML 23 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation
6 Months Ended
Mar. 29, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation
Note 5. Stock-Based Compensation

 

The Company has traditionally maintained incentive compensation plans that include provision for the issuance of equity-based awards. The Company established the 2008 Omnibus Equity Incentive Compensation Plan in 2008 (the “2008 Plan”) and has outstanding awards that were issued under the 2008 Plan. Subsequently, the 2008 Plan expired in 2018 and the Company established a new plan, the 2018 Omnibus Equity Incentive Plan (the “2018 Plan”) during the third fiscal quarter of 2018, pursuant to shareholder approval. Future awards will be issued under the 2018 Plan. Currently, the maximum number of shares available for issuance under the 2018 Plan is 1,050,000.

 

Stock-based compensation is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the requisite service period (generally the vesting period of the grant). The Company recognizes the impact of forfeitures as forfeitures occur.

 

Our net (loss) for the two quarters ended March 29, 2022 and March 30, 2021 includes $147,000 and $276,000, respectively, of compensation costs related to our stock-based compensation arrangements.

 

Stock Option awards

 

The Company measures the compensation cost associated with stock option awards by estimating the fair value of the award as of the grant date using the Black-Scholes pricing model. The Company believes that the valuation technique and the approach utilized to develop the underlying assumptions are appropriate in calculating the fair values of the Company’s stock options and stock awards granted during the two quarters ended March 29, 2022. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by the employees who receive equity awards.

 

In addition to the exercise and grant date prices of the stock option awards, certain weighted average assumptions that were used to estimate the fair value of stock option grants are listed in the following table:

 

   Two Quarters Ended March 29, 2022
Incentive and Non-Qualified Stock
Options
  Two Quarters Ended March 30, 2021
Incentive and Non-Qualified Stock
Options
       
Expected term (years)  6.5  3.63
Expected volatility  61.3%  74.62%
Risk-free interest rate  1.8%  0.24%
Expected dividends 
-
 
-

 

We estimate expected volatility based on historical weekly price changes of our common stock for a period equal to the current expected term of the options. The risk-free interest rate is based on the United States treasury yields in effect at the time of grant corresponding with the expected term of the options. The expected option term is the number of years we estimate that options will be outstanding prior to exercise considering vesting schedules and our historical exercise patterns.

 

The following table summarizes stock option activity for the two quarters ended March 29, 2022 under all plans:

 

   Shares   Weighted
Average
Exercise Price
   Weighted Average
Remaining
Contractual Life (Yrs)
 
             
Outstanding at beginning of year   443,815    $

3.63

    
 
 
Options granted   105,000    $4.90    
 
 
Options exercised   (28,797)  $3.10    
 
 
Outstanding March 29, 2022   520,018   $3.91    5.7 
Exercisable March 29, 2022   352,934   $3.57    5.1 

 

As of March 29, 2022, the aggregate intrinsic value of the outstanding and exercisable options was $567,000. Only options whose exercise price is below the closing price of the Company’s common stock as of March 29, 2022 are included in the intrinsic value calculation.

 

During the quarter ended March 29, 2022, the Company granted 25,000 non-qualified stock options to its Senior Vice President of Finance pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market Listing Rules as an inducement to employment at an exercise price of $3.95 per share. The options were granted on the Senior Vice President of Finance’s first day of employment on March 7, 2022 and vest ratably over a three-year period with a 10-year expiration date.

 

As of March 29, 2022, the total remaining unrecognized compensation cost related to non-vested stock options was approximately $283,000 and is expected to be recognized over a weighted average period of approximately 1.8 years.

 

There were 23,797 stock options exercised that resulted in an issuance of 23,797 shares during the two quarters ended March 29, 2022 with proceeds of approximately $90,000. There were 43,330 stock options exercised during the two quarters ended March 30, 2021 with proceeds of approximately $96,000.

 

Restricted Stock Units

 

During the two quarters ended March 29, 2022, there were 28,000 restricted stock units granted. For the two quarters ended March 30, 2021, there were no restricted stock units granted.

 

A summary of the status of non-vested restricted stock as of March 29, 2022 is presented below.

 

   Shares   Grant Date Fair
Value Per Share
        
Non-vested shares at beginning of year   61,952   $1.54 to $3.95
Granted   28,000   $4.50
Vested   (15,616)  $3.95
Non-vested shares at March 29, 2022   74,336   $1.54 to $4.50

 

As of March 29, 2022, there was $136,000 of total unrecognized compensation cost related to non-vested restricted stock. This cost is expected to be recognized over a weighted average period of approximately 0.7 years.

 

Restricted and Unrestricted Common Stock Awards

 

During the two quarters ended March 29, 2022 there were 9,256 unrestricted shares of common stock granted to directors of the Company. These shares had a grant date fair value of $4.35 per share which is equal to the closing price of the stock on the date of grant and resulted in the recognition of $40,000 of stock-based compensation expense. During the two quarters ended March 30, 2021, the Company granted its directors 12,948 shares of common stock and its Chief Executive Officer 10,000 performance shares from available shares under its 2018 Plan. The shares were issued with a grant date fair market value of $2.78 and $2.77, respectively, which is equal to the closing price of the stock on the date of grants. The performance shares granted to the Chief Executive Officer became fully vested on April 6, 2021 pursuant to the vesting provisions set forth in the grant notice.